Cybin Inc. (CYBN)

USD 6.5

(-1.81%)

Revenue Summary of Cybin Inc.

  • Cybin Inc.'s latest annual revenue in 2023 was - CAD , down 0.0% from previous year.
  • Cybin Inc.'s latest quarterly revenue in 2024 Q1 was - CAD , down 0.0% from previous quarter.
  • Cybin Inc. reported a annual revenue of - CAD in annual revenue 2022, down 0.0% from previous year.
  • Cybin Inc. reported a annual revenue of - CAD in annual revenue 2021, down -100.0% from previous year.
  • Cybin Inc. reported a quarterly revenue of - CAD for 2023 Q3, down 0.0% from previous quarter.
  • Cybin Inc. reported a quarterly revenue of - CAD for 2023 FY, down 0.0% from previous quarter.

Annual Revenue Chart of Cybin Inc. (2023 - 2016)

Historical Annual Revenue of Cybin Inc. (2023 - 2016)

Year Revenue Revenue Growth
2023 - CAD 0.0%
2022 - CAD 0.0%
2021 - CAD -100.0%
2020 864 Thousand CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2016 - CAD 0.0%

Peer Revenue Comparison of Cybin Inc.

Name Revenue Revenue Difference
AIM ImmunoTech Inc. 202 Thousand USD 100.0%
Armata Pharmaceuticals, Inc. 4.52 Million USD 100.0%
Actinium Pharmaceuticals, Inc. 81 Thousand USD 100.0%
Azitra, Inc. 686 Thousand USD 100.0%
Can-Fite BioPharma Ltd. 743 Thousand USD 100.0%
Chromocell Therapeutics Corporation - USD NaN%
Calidi Biotherapeutics, Inc. - USD NaN%
CEL-SCI Corporation - USD NaN%
iBio, Inc. 225 Thousand USD 100.0%
Lineage Cell Therapeutics, Inc. 8.94 Million USD 100.0%
MAIA Biotechnology, Inc. - USD NaN%
Matinas BioPharma Holdings, Inc. 1.09 Million USD 100.0%
NovaBay Pharmaceuticals, Inc. 14.72 Million USD 100.0%
NanoViricides, Inc. - USD NaN%
Oragenics, Inc. 37.65 Thousand USD 100.0%
BiomX Inc. -357 Thousand USD 100.0%
BiomX Inc. -357 Thousand USD 100.0%
Protalix BioTherapeutics, Inc. 65.49 Million USD 100.0%
Palatin Technologies, Inc. 4.49 Million USD 100.0%
Scorpius Holdings, Inc. 6.99 Million USD 100.0%
Theriva Biologics, Inc. - USD NaN%